【民報專訪】台灣清冠一號研發者蘇奕彰：台灣可望領先全球開發出治療困難疾病中藥

原文在此 

國家中醫藥研究所所長蘇奕彰認為，疫情讓台灣開發出一套可以因應疾病的中醫藥研發系統，這樣專病專方的模式已持續在其他重大疾病上使用，他信心十足地說道：「台灣可望成為領先全球開發出治療困難疾病的中藥！」

Yi-chang Su, director of the National Research Institute of Chinese Medicine, believes that the Covid-19 pandemic has made Taiwan develop a TCM research and development system that can respond to diseases. This model of special prescriptions for specific diseases has been continuously used in other major diseases. He said confidently: "Taiwan can take a lead in the world's search for the TCM treatment of difficult diseases!"

November 2022 Clinic Hours

New Patient Please Contact: joey0825@gmail.com

TSGH Neihu Main Facility Google Map

TSGH Tingchou Branch Google Map

This clinical research was conducted in our hospital and other hospitals in Taiwan. I am glad NRICM101 and NRICM 102 do help lots of patients in Taiwan and all over the world!

Curbing COVID-19 progression and mortality with traditional Chinese medicine among hospitalized patients with COVID-19: A propensity score-matched analysis

https://www.sciencedirect.com/science/article/pii/S1043661822003577

Yu-HweiTsenga1Sunny Jui-ShanLinb1Sheng-MouHoucChih-HungWangbShun-PingChengdKung-YenTsengeMing-YungLeefShen-MingLeegYi-ChiaHuangbChien-JungLinbChi-KueiLincTsung-LungTsaihChen-ShienLindMing-HueiChengiTieng-SiongFongeChia-I.TsaijYu-WenLukJung-ChihLinlYi-WenHuangeWei-ChenHsuhHsien-HwaKuodLi-HsiangWangmChia-ChingLiawaWen-ChiWeiaKeng-ChangTsaiaYuh-ChiangShenaWen-FeiChiouaJaung-GengLinanYi-ChangSua

Abstract

Background

Viral- and host-targeted traditional Chinese medicine (TCM) formulae NRICM101 and NRICM102 were administered to hospitalized patients with COVID-19 during the mid-2021 outbreak in Taiwan. We report the outcomes by measuring the risks of intubation or admission to intensive care unit (ICU) for patients requiring no oxygen support, and death for those requiring oxygen therapy.

Methods

This multicenter retrospective study retrieved data of 840 patients admitted to 9 hospitals between May 1 and July 26, 2021. After propensity score matching, 302 patients (151 received NRICM101 and 151 did not) and 246 patients (123 received NRICM102 and 123 did not) were included in the analysis to assess relative risks.

Results

During the 30-day observation period, no endpoint occurred in the patients receiving NRICM101 plus usual care while 14 (9.27%) in the group receiving only usual care were intubated or admitted to ICU. The numbers of deceased patients were 7 (5.69%) in the group receiving NRICM102 plus usual care and 27 (21.95%) in the usual care group. No patients receiving NRICM101 transitioned to a more severe status; NRICM102 users were 74.07% less likely to die than non-users (relative risk= 25.93%, 95% confidence interval 11.73%-57.29%).

Conclusion

NRICM101 and NRICM102 were significantly associated with a lower risk of intubation/ICU admission or death among patients with mild-to-severe COVID-19. This study provides real-world evidence of adopting broad-spectrum oral therapeutics and shortening the gap between outbreak and effective response. It offers a new vision in our preparation for future pandemics.